What is the ability of anti-cyclic citrullinated peptide antibodies determination in synovial fluid in discriminating rheumatoid arthritis from non-rheumatoid arthritis patients? A Tunisian cross-sectional study

2011 ◽  
Vol 31 (2) ◽  
pp. 375-379
Author(s):  
Dalila Mrabet ◽  
Lilia Laadhar ◽  
Héla Sahli ◽  
Béchir Zouari ◽  
Slim Haouet ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Synovial Fluid ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

scholarly journals The Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibodies (anti-CCP) in Patients with Rheumatoid Arthritis

2007 ◽  
Vol 26 (4) ◽  
pp. 285-288
Author(s):  
Ljubinka Damjanovska ◽  
Violeta Atanasovska ◽  
Todor Gruev
Keyword(s):  
Rheumatoid Arthritis ◽  
Diagnostic Value ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Mean Values ◽  
Cyclic Citrullinated Peptide ◽  
The Mean ◽  
Citrullinated Peptide ◽  
Peptide Antibodies ◽  
Latex Test

The Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibodies (anti-CCP) in Patients with Rheumatoid ArthritisA cross-sectional study was carried out to analyze the prevalence of anti-CCP antibodies and IgM RF in the sera of 160 randomly selected patients from the Rheumatology Department: 60 with RA, 50 with other rheumatic diseases (non-RA), 50 healthy controls (HC). The mean age of the group was 50.06+/-11.9 years. There were 141 females (88.1%) and 19 males (11.9%). RA patients fulfilled the revised ACR criteria. The mean duration of the disease was 82.4 months. Anti-CCP ELISA kit and IgM RF Latex test were used. The mean anti-CCP values were as follows: RA 60.4+/-57.6, non-RA 2.1+/-3.6, HC 1.3 +/-0.4 U/mL. Respectively, the mean values of IgM RF were: RA 515.8+/-525, non-RA 102+/-294, HC 15+/-57.5. Forty out of 60 (66.6%) RA patients were anti-CCP positive. Forty one out of 60 (68.3%) RA patients were positive for IgM RF. As expected, anti-CCP showed comparable sensitivity (66.8% vs. 68.3%) and higher specificity (98% vs. 87%) than IgM RF, at optimal cut-off values. The presence of either anti-CCP or IgM RF increased the testing sensitivity for the diagnosis of RA to 76.6%. AUC was greater for anti-CCP than for IgM RF (0.92 vs. 0.82).

High Levels of Anti-Cyclic Citrullinated Peptide Autoantibodies Are Associated with Co-occurrence of Pulmonary Diseases with Rheumatoid Arthritis

2011 ◽  
Vol 38 (6) ◽  
pp. 979-982 ◽  
Author(s):  
FLEUR AUBART ◽  
BRUNO CRESTANI ◽  
PASCALE NICAISE-ROLAND ◽  
FLORENCE TUBACH ◽  
CAROLINE BOLLET ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Lung Disease ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Cyclic Citrullinated Peptide ◽  
Independent Risk Factors ◽  
Male Sex ◽  
Citrullinated Peptide ◽  
Tomography Scan

Objective.To investigate whether levels of anti-cyclic citrullinated peptide antibodies (anti-CCP2) in patients with rheumatoid arthritis (RA) are associated with the co-occurrence of lung diseases.Methods.A total of 252 RA patients were included in a cross-sectional study. Pulmonary disease was confirmed by high-resolution chest computed tomography scan. Circulating anti-CCP2 were quantified using ELISA. Multivariate logistic regression was conducted to identify independent risk factors for lung disease.Results.Male sex (OR 3.29, 95% CI 1.59–6.80) and high anti-CCP2 levels (OR 1.49, 95% CI 1.25–1.78) were identified as independent risk factors for lung disease in the RA population.Conclusion.High anti-CCP2 levels are associated with lung disease in the RA population.

scholarly journals ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) ANTIBODIES IN PSORIATIC ARTHRITIS: A CROSS-SECTIONAL STUDY IN BRAZILIAN PATIENTS

2019 ◽  
Author(s):  
CRISTIANE GRUBER ◽  
THELMA LAROCCA SKARE ◽  
ANA PAULA BECKHAUSER DE CAMPOS ◽  
VINÍCIUS MAESTRI ◽  
BETANIA LONGO ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide

The outcome of patients with rheumatoid arthritis: a cross-sectional study

2019 ◽  
pp. 5-9
Author(s):  
Khaled Algohani ◽  
Muhannad Althobaiti ◽  
Sanad Alshammari ◽  
Fahad Alnahari ◽  
Ali Aldahhasi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional

Immuno-biological Assessments of Temporomandibular Joint Disease in Patients with Immune-mediated Rheumatic Conditions. A cross sectional study of 273 cases

2018 ◽  
Vol 68 (12) ◽  
pp. 2987-2991
Author(s):  
Cristina Iordache ◽  
Bogdan Vascu ◽  
Eugen Ancuta ◽  
Rodica Chirieac ◽  
Cristina Pomirleanu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Temporomandibular Joint ◽  
Final Analysis ◽  
Cross Sectional Study ◽  
Joint Disease ◽  
Sectional Study ◽  
Cross Sectional ◽  
Immune Parameters ◽  
Immune Mediated

Temporomandibular joint (TMJ) is commonly involved in various immune-mediated rheumatic disorders accounting for significant disability and impaired quality of life. The aim of our study was to assess inflammatory and immune parameters in patients with TMJ arthritis related to rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) and to identify potential relation with severity and dysfunction of TMJ pathology. We performed a cross-sectional study in a cohort of 433 consecutive RA, 32 JIA, 258 AS, and 103 PsA. Only patients presenting with clinically significant TMJ involvement (273) related to their rheumatic condition were included in the final analysis. TMJ involvement is traditionally described in chronic inflammatory rheumatic disorders, particularly in patients with higher levels of inflammation as detected in rheumatoid arthritis and psoriatic arthritis. Disease activity and severity, as well as biological and positive serological assessments (rheumatoid factor, anti-cyclic citrullinated peptide, IL-1) remain significant determinants of the severity of TMJ arthritis.

Sign in / Sign up

Export Citation Format

Share Document